Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients

Abstract Phenotypic improvement of hemoglobinopathies such as sickle cell disease and β-thalassemia (β-thal) has been shown in patients with high levels of Hb F. Among the drugs proposed to increase Hb F production, hydroxyurea (HU) is currently the only one proven to improve the clinical course of these diseases. However, Hb F increase and patient’s response are highly variable, indicating that new pharmacological agents could be useful for patients not responding to HU or showing a reduction of response during long-term therapy. In this study we evaluated the efficacy of rapamycin, a lypophilic macrolide used for the prevention of acute rejection in renal transplant recipients, as an inducer of Hb F production. The analyses were performed in cultured erythroid progenitors from 25 sickle cell disease and 25 β-thal intermedia (β-TI) patients. The use of a quantitative Real-Time-polymerase chain reaction ReTi-PCR technique and high performance liquid chromatography (HPLC) allowed us to determine the increase in γ-globin mRNA expression and Hb F production in human erythroid cells treated with rapamycin. The results of our study demonstrated an increase in vitro of γ-globin mRNA expression in 15 sickle cell disease and 14 β-TI patients and a corresponding Hb F increase. The induction by rapamycin, even if lower or similar in most of samples analyzed, in some cases was higher than HU. These data suggest that rapamycin could be a good candidate to be used in vivo for the treatment of hemoglobinopathies.

[1]  M. Steinberg,et al.  Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta‐thalassemia , 2014, European journal of haematology.

[2]  S. Swaminathan,et al.  Comparison of in-vitro and in-vivo response to fetal hemoglobin production and γ-mRNA expression by hydroxyurea in Hemoglobinopathies , 2013, Indian journal of human genetics.

[3]  G. Atweh,et al.  Pharmacologic induction of fetal hemoglobin production. , 2010, Hematology/oncology clinics of North America.

[4]  R. Calzolari,et al.  Desensitization to hydroxycarbamide following long‐term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients , 2010, British journal of haematology.

[5]  R. Calzolari,et al.  Induction of gamma‐globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients , 2008, British journal of haematology.

[6]  S. Perrine.  Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. , 2008, Pediatric annals.

[7]  O. Platt,et al.  Hydroxyurea for the treatment of sickle cell anemia. , 2008, The New England journal of medicine.

[8]  Roberto Gambari,et al.  Effects of rapamycin on accumulation of α‐, β‐ and γ‐globin mRNAs in erythroid precursor cells from β‐thalassaemia patients , 2006 .

[9]  A. Mancuso,et al.  Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long‐term follow up , 2006, British journal of haematology.

[10]  R. Calzolari,et al.  Allele-specific transcription of fetal genes in primary erythroid cell cultures from Lepore and δβ° thalassemia patients , 2005 .

[11]  A. Cnaan,et al.  Survival and Complications in Thalassemia , 2005, Annals of the New York Academy of Sciences.

[12]  E. Vichinsky,et al.  The role of fetal hemoglobin-enhancing agents in thalassemia. , 2004, Seminars in hematology.

[13]  Roberto Gambari,et al.  Rapamycin‐mediated induction of γ‐globin mRNA accumulation in human erythroid cells , 2004 .

[14]  Roberto Gambari,et al.  Accumulation of γ‐globin mRNA in human erythroid cells treated with angelicin , 2003, European journal of haematology.

[15]  M. Bradai,et al.  Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. , 2003, Blood.

[16]  S. Sehgal.  Sirolimus: its discovery, biological properties, and mechanism of action. , 2003, Transplantation proceedings.

[17]  M. Steinberg,et al.  Pharmacologic Modulation of Fetal Hemoglobin , 2001, Medicine.

[18]  M. Metcalfe,et al.  Rapamycin in transplantation: a review of the evidence. , 2001, Kidney international.

[19]  B D Kahan,et al.  Clinical Pharmacokinetics of Sirolimus , 2001, Clinical pharmacokinetics.

[20]  D J Weatherall,et al.  Inherited haemoglobin disorders: an increasing global health problem. , 2001, Bulletin of the World Health Organization.

[21]  A. Schechter,et al.  Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. , 2000, Blood.

[22]  J. Gummert,et al.  Newer immunosuppressive drugs: a review. , 1999, Journal of the American Society of Nephrology : JASN.

[23]  N. Olivieri,et al.  Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in β thalassaemia , 1998, British journal of haematology.

[24]  H. Bunn.  Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.

[25]  R. Calzolari,et al.  Clinical and hematological response to hydroxyurea in a patient with Hb Lepore/beta-thalassemia. , 1997, Hemoglobin.

[26]  H. Drexler,et al.  The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines. , 1997, Leukemia research.

[27]  A. Schechter,et al.  Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. , 1996, Blood.

[28]  N. Olivieri.  Reactivation of fetal hemoglobin in patients with beta-thalassemia. , 1996, Seminars in hematology.

[29]  A. Schechter,et al.  Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. , 1993, Blood.

[30]  A. Schechter,et al.  3 Sickle cell disease pathophysiology , 1993 .

[31]  A. Oppenheim,et al.  Proliferation and maturation of human erythroid progenitors in liquid culture. , 1989, Blood.